期刊
DRUG AND ALCOHOL DEPENDENCE
卷 79, 期 1, 页码 1-10出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.drugalcdep.2004.11.013
关键词
opioids; women; buprenorphine; methadone; NAS; infants; prenatal
资金
- NCRR NIH HHS [M01RR-02719] Funding Source: Medline
- NIDA NIH HHS [DA R01 12220] Funding Source: Medline
This study was designed to compare the neonatal abstinence syndrome (NAS) in neonates of methadone and buprenorphine maintained pregnant opioid-dependent women and to provide preliminary safety and efficacy data for a larger multi-center trial. This randomized, double-blind, double-dummy, flexible dosing, parallel-group controlled trial was conducted in a comprehensive drug-treatment facility that included residential and ambulatory care. Participants were opioid-dependent pregnant women and their neonates. Treatment involved daily administration of either sublingual buprenorphine or oral methadone using flexible dosing of 4-24 mg or 20- 100 mg, respectively. Primary a priori outcome measures were: (1) number of neonates treated for NAS; (2) amount of opioid agonist medication used to treat NAS; (3) length of neonatal hospitalization; and (4) peak NAS score. Two of 10 (20%) buprenorphine-exposed and 5 of 11 (45.5%) methadone-exposed neonates were treated for NAS (p =.23). Total amount of opioid-agonist medication administered to treat NAS in methadone-exposed neonates was three times greater than for buprenorphine-exposed neonates (93.1 versus 23.6; p =. 13). Length of hospitalization was shorter for buprenorphine-exposed than for methadone-exposed neonates (p =.021). Peak NAS total scores did not significantly differ between groups (p =.25). Results suggest that buprenorphine is not inferior to methadone on outcome measures assessing NAS and maternal and neonatal safety when administered starting in the second trimester of pregnancy. (c) 2004 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据